Akebia terminates Vafseo license with CSL Vifor, sets royalty payments and buy-down option

Akebia Therapeutics, Inc.

License agreement terminated immediately for business reasons; Akebia regains full U.S. marketing rights for Vafseo.
Akebia to repay $40M working capital fund via quarterly tiered royalties of 8-14% of net sales through May 2028.
Settlement royalties: high single-digit % on net sales up to $450M, mid-single % above; buy-down option from July 2027.
Amended $55M Kreos loan facility to include covenants linked to the termination agreement.
Royalty payments commence July 1, 2025; minimum true-up milestones of $10M, $20M, $40M by 2026-2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.